132 related articles for article (PubMed ID: 36093511)
1. Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer.
Nishimoto M; Fujita K; Yamamoto Y; Hashimoto M; Adomi S; Banno E; Saito Y; Shimizu N; Mori Y; Minami T; Nozawa M; Nose K; Hirayama A; Yoshimura K; Uemura H
Transl Cancer Res; 2022 Aug; 11(8):2681-2687. PubMed ID: 36093511
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review.
Chen WJ; Kong DM; Li L
Asian J Androl; 2021; 23(2):163-169. PubMed ID: 33159024
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
4. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
5. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer.
Zhao J; Sun G; Liao B; Zhang X; Armstrong CM; Yin X; Liu J; Chen J; Yang Y; Zhao P; Tang Q; Wang Z; Chen Z; Li X; Wei Q; Li X; Chen N; Gao AC; Shen P; Zeng H
BJU Int; 2018 Dec; 122(6):994-1002. PubMed ID: 29772102
[TBL] [Abstract][Full Text] [Related]
6. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
7. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
Ahmadzadehfar H; Rahbar K; Baum RP; Seifert R; Kessel K; Bögemann M; Kulkarni HR; Zhang J; Gerke C; Fimmers R; Kratochwil C; Rathke H; Ilhan H; Maffey-Steffan J; Sathekge M; Kabasakal L; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):113-122. PubMed ID: 32383093
[TBL] [Abstract][Full Text] [Related]
8. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
[No Abstract] [Full Text] [Related]
9. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer.
Zhang BY; Riska SM; Mahoney DW; Costello BA; Kohli R; Quevedo JF; Cerhan JR; Kohli M
BJU Int; 2017 Mar; 119(3):489-495. PubMed ID: 27410686
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
11. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy.
Zhao J; Shen P; Sun G; Chen N; Liu J; Tang X; Huang R; Cai D; Gong J; Zhang X; Chen Z; Li X; Wei Q; Zhang P; Liu Z; Liu J; Zeng H
Oncotarget; 2017 Aug; 8(33):55374-55383. PubMed ID: 28903426
[TBL] [Abstract][Full Text] [Related]
12. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
[TBL] [Abstract][Full Text] [Related]
13. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
Lorente D; Llacer C; Lozano R; de Velasco G; Romero-Laorden N; Rodrigo M; Sánchez-Iglesias Á; di Capua C; Castro E; Ferrer C; Sánchez-Hernández A; Olmos D
Eur Urol; 2021 Nov; 80(5):641-649. PubMed ID: 34373138
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.
Omlin A; Pezaro C; Mukherji D; Mulick Cassidy A; Sandhu S; Bianchini D; Olmos D; Ferraldeschi R; Maier G; Thompson E; Parker C; Attard G; de Bono J
Eur Urol; 2013 Aug; 64(2):300-6. PubMed ID: 23313031
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer.
Shiota M; Kobayashi T; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
Urol Oncol; 2019 Nov; 37(11):813.e21-813.e26. PubMed ID: 31202731
[TBL] [Abstract][Full Text] [Related]
18. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.
Anton A; Pillai S; Semira MC; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Baenziger O; Gibbs P; Tran B
BJUI Compass; 2022 May; 3(3):205-213. PubMed ID: 35492221
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
20. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
